Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Sunshine Biopharma (NASDAQ:SBFM) announced on October 16, 2025 that its wholly owned Canadian subsidiary, Nora Pharma, has launched Pravastatin, a generic version of Pravachol for lowering LDL and raising HDL cholesterol.
Product details: available strengths 10 mg, 20 mg, 40 mg, sold in bottles of 100 tablets. Market context: IQVIA estimates the Canadian cholesterol‑lowering market at USD $582 million by end of 2025 and a projected CAGR of 8% to USD $1.07 billion by 2033; Biospace projects the global lipid‑lowering market to exceed USD $46.58 billion by 2033.
Sunshine Biopharma (NASDAQ:SBFM) announced on October 14, 2025 that its Board approved a $5 million strategic investment in Bitcoin (BTC) as a treasury reserve asset.
The Company said the $5 million position will be acquired over time via a regulated digital asset custodian or by buying an ETF or proxy stock, and that it may allocate additional funds to increase Bitcoin holdings in the future. Management framed the move as a hedge and a high-conviction asset to strengthen the company's financial foundation while continuing focus on its drug development pipeline, including antiviral small molecules and mRNA-based cancer therapies.
Sunshine Biopharma (NASDAQ:SBFM) and the University of Arizona announced a new series of orally active, non‑covalent PLpro protease inhibitors that show dose‑dependent antiviral activity in mice infected with SARS‑CoV‑2. The compounds are potent against the PLpro enzyme, exhibited dose‑dependent efficacy in cellular SARS‑CoV‑2 models, and displayed favorable pharmacokinetic profiles in mice, rats and dogs. The program follows an initial PLpro library published in August 2024 in Journal of Medicinal Chemistry. Ongoing work includes dose‑dependent efficacy analysis in infected mice and further preclinical evaluation.
Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of NIOPEG®, its first biosimilar drug, through its Canadian subsidiary Nora Pharma. NIOPEG® is comparable to NEULASTA® (Pegfilgrastim) and is designed to reduce infection risk in chemotherapy patients with non-myeloid malignancies.
The global market for NEULASTA® and its biosimilars was valued at $4.5 billion in 2024, with projections to reach $9.2 billion by 2033, growing at a CAGR of 8.5%. In Canada, where biologic drug sales reached $10 billion in 2020, the market represents a significant opportunity due to high per capita biologics spending and favorable provincial switching policies.
Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of Everolimus, a generic oncology drug, in the Canadian market through its subsidiary Nora Pharma Inc. Everolimus, a generic equivalent of Afinitor®, is designed to treat multiple conditions including advanced renal cell carcinoma, HER2-negative breast cancer, neuroendocrine tumors, and subependymal giant cell astrocytoma.
The drug is available in 2.5 mg, 5 mg, and 10 mg strengths in 30-tablet blister packs. The global Everolimus market, valued at $2.5 billion in 2023, is projected to reach $4.8 billion by 2032 with a 7.1% CAGR. The Canadian market segment represents approximately 2.2% of the global market and is growing at a 6.4% CAGR.
Sunshine Biopharma (NASDAQ:SBFM) has successfully closed its previously announced registered direct offering, raising approximately $2.46 million through the sale of Common Stock and pre-funded warrants to institutional investors. The offering, priced at $2.07 per share, included 1,188,404 shares of Common Stock or Pre-Funded Warrants.
The Pre-Funded Warrants, priced at $2.06999 with an exercise price of $0.00001, are immediately exercisable. The transaction, which closed on April 3, 2025, was conducted under Nasdaq rules at market price. The company plans to utilize the net proceeds for general corporate purposes and working capital.
Aegis Capital Corp. served as the exclusive placement agent, with legal representation from various firms. The offering was executed through an effective shelf registration statement on Form S-3.
Sunshine Biopharma (NASDAQ:SBFM) has announced a $2.46 million registered direct offering with institutional investors, priced at $2.07 per share of Common Stock under Nasdaq rules. The offering includes 1,188,404 shares of Common Stock or Pre-Funded Warrants, with the latter priced at $2.069 with a $0.001 exercise price.
The Pre-Funded Warrants will be immediately exercisable until fully exercised. The transaction is expected to close around April 3, 2025, subject to customary conditions. The company plans to use the proceeds for general corporate purposes and working capital. Aegis Capital Corp is serving as the exclusive placement agent.
The offering is being conducted through an effective shelf registration statement on Form S-3, previously declared effective by the SEC on January 15, 2025.